Koers Revive Therapeutics Ltd Toronto S.E.
Aandelen
RVV
CA7615161030
Biotechnologie & Medisch Onderzoek
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
- CAD | -.--% |
|
+6,67% | -11,11% |
Omzet 2022 | - | Omzet 2023 | - | Marktkapitalisatie | 16,09 mln. 21,99 mln. 15,02 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -17 mln. -23,22 mln. -15,87 mln. | Nettowinst (verlies) 2023 | -6 mln. -8,2 mln. -5,6 mln. | EV/omzet 2022 | - |
Nettoliquiditeiten 2022 | 3,59 mln. 4,9 mln. 3,35 mln. | Nettoliquiditeiten 2023 | 1,87 mln. 2,55 mln. 1,74 mln. | EV/omzet 2023 | - |
K/w-verhouding 2022 |
-8,26
x | K/w-verhouding 2023 |
-2,42
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 98,54% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Michael Frank
CEO | Chief Executive Officer | - | 18-12-19 |
Carmelo Marrelli
DFI | Director of Finance/CFO | 53 | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Michael Frank
CEO | Chief Executive Officer | - | 18-12-19 |
William Jackson
BRD | Director/Board Member | - | 01-01-14 |
Andrew Lindzon
BRD | Director/Board Member | 63 | 18-12-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,45% | 123 mld. | |
+21,96% | 115 mld. | |
+23,73% | 25,85 mld. | |
-20,05% | 20,9 mld. | |
-16,28% | 16,77 mld. | |
-16,52% | 16,52 mld. | |
-44,35% | 15,56 mld. | |
+63,91% | 15,49 mld. | |
+2,52% | 13,45 mld. |